Narrative review on efficacy and safety of anti-angiogenesis in combination with immunotherapy in the treatment of breast cancer.

Transl Breast Cancer Res · 2024 · PMC11557168 · PMID 39534580

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

The GeparNUEVO trial used durvalumab plus chemotherapy as neoadjuvant therapy for TNBC and observed an increase in pCR, improvement in invasive disease-free survival (iDFS) and distant disease-free survival (DDFS), and a favorable trend in OS ( 60 ).

also in 714 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.